Sulcardine, an investigational multichannel blocker for atrial fibrillation with uniquely intense JTp inhibition to enhance safety

1 September 2024 (15:00 - 15:50)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Doctor Jay Mason

University of Utah, Salt Lake City (United States of America)

8 More presentations in this session

Presentation thumbnail

Cluster-specific predictors of early rhythm control in contemporary European cohort of patients with atrial fibrillation: The EHRA-PATHS Project

Doctor M. Mihajlovic (Belgrade, RS)

Abstract Slides Video

Presentation thumbnail

Impact of rhythm control strategy on outcomes in patients with first diagnosed atrial fibrillation in an 11-year real-world registry

Doctor C. Salbach (Heidelberg, DE)

Abstract Slides Video

Presentation thumbnail

Atrial function after cardioversion in patients with persistent atrial fibrillation

Doctor K. Noda (Sendai, JP)

Abstract Slides Video

Presentation thumbnail

Sinus rhythm maintenance and the changes of echocardiographic parameters in patients with late persistent atrial fibrillation at 6 months after direct current cardioversion

Doctor Y. Skybchyk (Kiev, UA)

Abstract Slides Video

Presentation thumbnail

H558R: a common polymorphism may modify the efficacy and toxicity of flecainide in maintaining sinus rhythm; a cohort study.

Mr M. Trincado Ave (Santiago de Compostela, ES)

Abstract Slides Video

Access the full session

Session thumbnail

Rhythm control in atrial fibrillation: prognostic and therapeutic implications

The Event

Event poster

ESC Congress 2024

1 September 2024 15:00 CET

You may be interested in

Congress Presentation

Promising electrical targets for novel antiarrhythmic strategies in atrial fibrillation

Congress Presentation

New AADs: what's in the pipeline?

Congress Presentation

New targeted antiarrhythmic drugs

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources